{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:39:18Z","timestamp":1792463958100,"version":"4.5.0"},"reference-count":9,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"DOI":"10.36401\/jipo-26-17","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:08:07Z","timestamp":1792170487000},"page":"254-259","source":"Crossref","is-referenced-by-count":0,"title":["Clinical, Radiologic, and Highest-Grade Assessment of Immune Checkpoint Inhibitor Pneumonitis in Non\u2013Small Cell Lung Cancer"],"prefix":"10.36401","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-8316","authenticated-orcid":true,"given":"Felipe","family":"Soto","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Department of Medicine, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Anees","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary, Critical Care and Sleep Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia A.","family":"Faiz","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-156X","authenticated-orcid":true,"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[{"name":"Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-9-4-254-b01","series-title":"N Engl J Med","first-page":"1823","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","unstructured":"Reck M,\nRodr\u00edguez-Abreu D,\nRobinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u20131833. DOI: 10.1056\/NEJMoa160677427718847"},{"key":"i2590-017X-9-4-254-b02","series-title":"N Engl J Med","first-page":"1627","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","unstructured":"Borghaei H,\nPaz-Ares L,\nHorn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u20131639. DOI: 10.1056\/NEJMoa150764326412456"},{"key":"i2590-017X-9-4-254-b03","series-title":"Lancet","first-page":"255","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The","volume":"389","author":"Rittmeyer","year":"2017","unstructured":"Rittmeyer A,\nBarlesi F,\nWaterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The. Lancet. 2017;389:255\u2013265. DOI: 10.1016\/S0140-6736(16)32517-X27979383"},{"key":"i2590-017X-9-4-254-b04","series-title":"Lancet Oncol","first-page":"1497","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","unstructured":"Langer CJ,\nGadgeel SM,\nBorghaei H, et al. KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497\u20131508. DOI: 10.1016\/S1470-2045(16)30498-327745820"},{"key":"i2590-017X-9-4-254-b05","series-title":"JAMA Oncol","first-page":"1721","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","unstructured":"Wang DY,\nSalem J-E,\nCohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 2018;4:1721\u20131728. DOI: 10.1001\/jamaoncol.2018.392330242316"},{"key":"i2590-017X-9-4-254-b06","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"Nov 27, 2017","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Nov 27, 2017. ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"i2590-017X-9-4-254-b07","series-title":"J Natl Compr Canc Netw","first-page":"582","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","unstructured":"Thompson JA,\nSchneider BJ,\nBrahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024;22:582\u2013592. DOI: 10.6004\/jnccn.2024.005739536465"},{"key":"i2590-017X-9-4-254-b08","series-title":"Ann Oncol","first-page":"1217","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","unstructured":"Haanen J,\nObeid M,\nSpain L, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u20131238. DOI: 10.1016\/j.annonc.2022.10.00136270461"},{"key":"i2590-017X-9-4-254-b09","series-title":"Eur Rev Med Pharmacol Sci","first-page":"97","article-title":"Discrepancy between clinical and radiological responses in non-infectious pneumonia during immunotherapy: a case report","volume":"29","author":"Pezzuto","year":"2025","unstructured":"Pezzuto A,\nRicci A,\nPalermo T, et al. Discrepancy between clinical and radiological responses in non-infectious pneumonia during immunotherapy: a case report. Eur Rev Med Pharmacol Sci. 2025;29:97\u2013101. DOI: 10.26355\/eurrev_202502_3710040026136"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/4\/article-p254.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/4\/article-p254.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/4\/article-p254.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:33Z","timestamp":1792461033000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/4\/article-p254.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":9,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.36401\/jipo-26-17","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,16]]}}}